Jade Biosciences Inc. (JBIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Jade Biosciences: Duration Is The Real Product
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.
Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the antibody into patient studies for IgA nephropathy.
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 7 | $91.78 | $155.68 | $63.9 | 69.62% |
| NA Nizar Araji National Bank Of Canada /FI/ | 23 | $511.06 | $505.08 | -$5.98 | -1.17% |
 John H. Burbank III Passport Capital LLC | 1.23M | $18.99M | $30.4M | $11.42M | 60.14% |
 Point72 Asset Management LP Point72 Asset Management LP | 167,204 | $2.58M | $4.13M | $1.55M | 60.14% |
 David Kim Paradigm Biocapital Advisors LP | 2.86M | $63.49M | $70.61M | $7.11M | 11.21% |
Jade Biosciences Inc. (JBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jade Biosciences Inc. ever had a stock split?
Jade Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Tom Frohlich CEO | NASDAQ (CM) Exchange | 008064206 CUSIP |
| US Country | 55 Employees | 29 Apr 2025 Last Dividend | 29 Apr 2025 Last Split | - IPO Date |
Overview
Jade Biosciences, Inc. is a pioneering biotechnology company dedicated to the advancement of innovative therapies that target critical unmet needs in autoimmune diseases. The organization is committed to enhancing patient outcomes through the development of effective treatments. Its flagship product, JADE-001, has garnered attention for its unique approach to addressing immunoglobulin A (IgA) nephropathy by specifically targeting the anti-A PRoliferation-Inducing Ligand (APRIL) pathway. Anticipated to progress into clinical trials in the latter half of 2025, JADE-001 holds the promise of delivering crucial data to healthcare professionals in the first half of 2026. In addition to its main focus, Jade Biosciences is actively expanding its portfolio with two promising preclinical antibody programs, JADE-002 and JADE-003, which aim to further contribute to the field of autoimmune disease management.
Products and Services
- JADE-001: This is the leading therapy developed by Jade Biosciences, designed to address IgA nephropathy through the APRIL pathway. By inhibiting key mechanisms that exacerbate the disease, JADE-001 aims to provide a new solution for patients suffering from this challenging condition. The drug is set to enter clinical trials in late 2025, with initial clinical data expected to emerge in 2026.
- JADE-002: A preclinical antibody program that focuses on exploring innovative mechanisms for addressing autoimmune-related disorders. While details are still under wraps, JADE-002 is anticipated to complement the existing pipeline and provide additional options for treating patients with significant unmet medical needs.
- JADE-003: Another promising preclinical antibody program, JADE-003 enhances the company's commitment to discovering new therapies for autoimmune diseases. Similar to JADE-002, detailed information is still being developed, but JADE-003 is expected to undergo further research and development to determine its efficacy in the broader context of immune system modulation.
